2017 World Medical Innovation Forum: Cardiovascular, May 1-3, 2017, Partners HealthCare, Boston, at the Westin Hotel, Boston
Reporter: Aviva Lev-Ari, PhD, RN
ANNOUNCEMENT
Leaders in Pharmaceutical Business Intelligence (LPBI) Group will cover the event in REAL TIME
Aviva Lev-Ari, PhD, RN will be streaming live from the floor of the Westin Hotel in Boston on May 1-3, 2017
Biggest Voices in Cardiovascular Care
2017 World Medical Innovation Forum: Cardiovascular, May 1-3, 2017, Partners HealthCare, Boston, at the Westin Hotel, Boston
UPDATED on 3/29/2017
Partners Media Contact: Rich Copp
617-278-1031 rcopp@partners.org
REINVENTING CARDIOVASCULAR AND CARDIOMETABOLIC CARE FOCUS OF GLOBAL GATHERING
BOSTON — March 29, 2017 — Partners HealthCare, the nation’s largest academic research enterprise, today announced the third annual World Medical Innovation Forum, which will bring together nearly 1,000 international cardiovascular innovation decision-makers from industry, investment, clinical and research communities from May 1 to May 3, 2017 in Boston.
The focus of the Forum is the new technologies and systems that are transforming the largest market in healthcare. Keynoters include the CEOs of Amgen, Boston Scientific, Medtronic, Philips, Cardinal Health, Abiomed, Alnylam, Bard, Edwards, Medicines Company, Moderna, MyoKardia, Yumanity, Zoll, Boehringer Ingelheim, American Heart Association, GE Healthcare, Siemens Healthcare, and GE Ventures. They will be joined by top investors, the head of National Heart Lung and Blood Institute, Gary Gibbons, MD, the former FDA commissioner, Robert Califf, MD, and key leaders from the Centers for Medicare and Medicaid Services. There will be more than 120 speakers in total—all experts from industry, government, the investment community and Harvard Medical School. World Forum attendees include senior executives, investors, entrepreneurs, clinicians and scientists.
“The Forum will highlight the remarkable convergence occurring across different industries around the redesign of cardiovascular care,” says Calum MacRae, MD, PhD, Chief of Cardiovascular Medicine at Brigham and Women’s Hospital and Associate Professor of Medicine at Harvard Medical School. “The outcomes of this cooperation between academia and industry will impact the lives of millions of patients worldwide.”
Over three days, the Forum will review in detail the emerging cardiovascular therapies, ’omics, digital diagnostics, education and engagement with new delivery platforms to that will become the model of care for cardiovascular and related metabolic diseases.
The Forum is co-chaired by MacRae and Anthony Rosenzweig, MD, Chief, Cardiology Division at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. Academic speakers will include dozens of senior Harvard Medical School-appointed clinicians and investigators from Brigham and Women’s Hospital, Massachusetts General Hospital and Newton-Wellesley Hospital including the Presidents of all three hospitals.
“The changing spectrum of heart disease has produced new clinical needs, and marshaling an effective response will require cooperation among a diverse array of stakeholders. Technology, patient insights and clinical management have been combined to propel diagnosis, treatment and long term care into a new era,” said Anthony Rosenzweig, MD. “This global gathering of top cardiovascular leaders will catalyze new connections, conversations and thinking around these opportunities.”
Among the many features of the Forum is announcement of the “Disruptive Dozen,” the technologies likely to have the greatest impact on cardiovascular and cardiometabolic care in the next decade.
The Forum will kick off with 10-minute rapid-fire presentations by BWH and MGH early career Harvard faculty leaders describing the clinical potential of their work. Discovery Café workshops will follow, led by senior Harvard faculty addressing cutting-edge cardiovascular challenges.
The World Medical Innovation Forum is organized by Partners HealthCare Innovation, a division of Partners HealthCare dedicated to advancing the commercial application of the unique capabilities of Partners’ Harvard faculty.
Sponsors of the Forum include Boston Scientific, Amgen, Lilly, GE, Pfizer, AstraZeneca, Bayer, Bard, Edwards Lifesciences, Mintz Levin, Medtronic and Novo Nordisk.
About the World Medical Innovation Forum
The World Medical Innovation Forum is a global gathering of senior corporate, investor and academic leaders. It was established to respond to the intensifying transformation of health care and its impact on innovation. The Forum is rooted in the belief that no matter the magnitude of that change, the center of health care needs to be a shared, fundamental commitment to collaborative innovation—industry and academia working together and its ability to improve patient lives.
For more information or to register, please go to www.worldmedicalinnovation.org.
About Partners HealthCare
Partners HealthCare is an integrated health system founded by Brigham and Women’s Hospital and Massachusetts General Hospital. The Partners system includes academic, community and specialty hospitals, a managed care organization, community health centers, a physician network, home health and long-term care services, and other health-related entities. Partners HealthCare is one of the nation’s leading biomedical research organizations and a principal teaching affiliate of Harvard Medical School. Partners HealthCare is a non-profit organization.
###
Monday, May 1, 2017
First Look: The Next Wave of Cardiology Breakthroughs
Harvard Medical School investigators describe their most promising work in rapid fire presentations highlighting commercial opportunities in cardiovascular and cardiometabolic care. Twenty rising stars from Brigham and Women’s Hospital and Massachusetts General Hospital will present in 10-minute sessions.
Concurrent Discovery Cafés Breakout Sessions: Sharing Perspectives
Top Cardiology faculty from Brigham and Women’s Hospital and Massachusetts General Hospital address compelling topics in clinical research and implementation of care.
Topics to be covered include:
- Cardiac Replacement Therapy: The Next Ten Years
- Heart Failure: Back in The Game through New Pathways
- Payment Models: Provider’s Perspective
- Microbiome: Implications for Cardiovascular and Metabolic Disease
- Molecular Imaging: New Biological Endpoints – Function Over Structure
- Technology: Enhancing Translational Medicine
Reinventing Cardiac Care
Two renowned clinical leaders provide an overview of the medical and economic challenges that cardiovascular and cardiometabolic disorders present.
They will highlight strategic direction in cardiac research and clinical care at Partners, and address how recent trends in investment, regulation, and policy may be dovetailed with efforts at Partners.
The experts also spotlight for attendees the various therapies, diagnostics, devices, and critical issues that will be discussed throughout the upcoming 2.5 days of the World Medical Innovation Forum.
CEO Roundtable: Today’s Learning, Tomorrow’s Opportunities
Discussion on contribution of technology innovation to the treatment of cardiovascular disease reflecting on lessons and how they shape investment decisions.
Tackling the AFib Epidemic
Evolving trends in diagnosis, prevention, and treatment of atrial fibrillation. Factors that will influence patient care over the next 5 years are considered, including risk stratification, procedure and technology options, and potential implications of CMS policies, such as bundling.
Heart Failure’s Therapeutic Mandate
One million patients are hospitalized annually for HF—80% of total US cost of HF management. After discharge from HF hospitalization, 24% are rehospitalized within 30 days, greater than 50% within 6 months. Perspective on disease management, addressing the issues of hospital readmission and optimizing therapies.
CLINICAL HIGHLIGHT: A New Chapter of PAD
PAD is the most challenging atherosclerotic syndrome, largely due to the technological challenges of managing peripheral artery disease through minimally invasive strategies. Top physician, governmental, and industry leaders in the field discuss the potential for new breakthroughs including novel implantable devices, pharmacologic approaches, and reductions in associated cardiovascular morbidity and mortality.
The panel will also discuss, Below The Knee: The Persisting Unmet Need
Tuesday, May 2, 2017
FOCUS SESSION: Japan Today: Advancing Cardiometabolic Therapies
Discussion on unique aspects of cardiometabolic market in Japan, its projected trend over the next 5 years and explore transformative models of open innovation to accelerate development of new therapeutic options.
Pricing to Enable Affordability and Innovation
Balancing acceptable answers to high and escalating drug prices in the United States while making strides in medical innovation. Leaders in innovation, policy, care delivery, academia, and insurance discuss potential collaborative solutions.
CLINICAL HIGHLIGHT: Emerging Devices for Complex Structural Heart Disease
Evolution of mitral disease management, current practice and impact of new technologies on both repair and replacement, implications of a heterogeneous patient population, triage, timing of intervention.
Personal Monitoring for Disease Management
Considering the evolving trends in viability and utilization and the opportunities wearables may present for real-world clinical decision making.
Global Clinical Trials: Next Generation Design and Scalability
Cardiovascular trials currently account for 10 percent of all clinical trial participants. Discussion on design and implementation of clinical studies globally, considering strategies for patient access, regulatory implications, cost containment and management of relationships with global service providers.
Precision Cardiovascular Medicine: What is Different This Time
Explore how precision medicine is changing the face of cardiovascular medicine specifically. The session will examine the impact of combined phenotypic and genotypic characterization on optimizing response to therapeutics, trial design, improving outcomes, and redefining reimbursement.
CV Investing in the Next Decade
View on investing landscape, opportunities in the CV/metabolic marketplace, the drugs, devices and diagnostics currently in pipelines and notable positive trends.
CLINICAL HIGHLIGHT: Optimizing Care for the 51%: New Market Opportunities
Introduction: Cathy Minehan, Chair, MGH Corporation
Address implications of gender as a key biological factor for personalized medicine. Stroke is likely to be the first cardiovascular event, tied to AF and secondarily to hypertension. Opportunities for medication utilization and optimization in context of, manifestation of disease and understanding the biology, complications, strategies to collect relevant clinical evidence, and treatment response.
Disruptive Therapeutic Platforms: New Tools, New Outcomes
Recent advances of biological drugs have broadened the scope of therapeutic targets for a variety of human diseases. This holds true for dozens of RNA-based therapeutics currently under clinical investigation for diseases including heart failure. These emerging drugs could be considered in context of genomic/germ line screening, family history and epigenetics.
Wednesday, May 3, 2017
Innovation in Translational Trials
CV/metabolic disorders comprise aggregates of many niche diseases that may be targeted with therapies against specific molecular alterations, yet the final potential markets are much larger. This model creates challenges for both drug development and patient care with implications for initial indication selection and design and execution of clinical trials – from first-in-human through post marketing studies.
New Targets in Coronary Artery Disease
Cardiovascular trials have a proud history of providing some of the most robust data in evidence-based medicine. However the growing size and complexity of these trials imperils their future. This panel will discuss the design and implementation of clinical studies globally, considering strategies for patient access, leveraging electronic health records and mobile device data, personalized medicine, regulatory implications, cost containment and management of relationships with global service providers.
The Skinny on Fat: Therapeutic Opportunities
Explore the evolving role of adipose tissue as an active endocrine organ and discuss the possibilities to discover novel signaling pathways relevant to cardiovascular health and viable druggable targets.
@@@@
|
||||||||||||||||||||||||||||||||||||||||||||||||||
SOURCE
From: Partners HealthCare Innovation <innovations@partners.org>
Date: Wednesday, December 14, 2016 at 9:47 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Cardiovascular’s next chapter of innovation begins now.
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22
Leave a Reply